In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 1566.44 with a ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Telehealth providers like Hims and Ro say they are helping fill the gap. Their business model offers patients quick access to ...

Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Pharmaceutical giants are squaring off against telehealth companies and pharmacies selling custom-made versions of the hot ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Hims & Hers Health. Looking at options history for Hims & Hers Health (NYSE:HIMS) we detected 16 trades. If we ...

Hims & Hers went public via a SPAC deal in January 2021. Co-founder and CEO Andrew Dudum was a Business Times 40 Under 40 honoree in 2020. The company waded into controversy over the past few months.